GLP-1 Receptor Agonists Show Preliminary Efficacy for Hidradenitis Suppurativa as Adjunct Therapy

Hidradenitis suppurativa (HS) is a debilitating chronic inflammatory skin disease characterized by painful nodules and abscesses, significantly impacting patient quality of life. Its complex pathogenesis involves immune dysregulation, metabolic disturbances, and hormonal influences, often co-occurring with obesity and metabolic syndrome. Current treatments often fall short, leaving a need for novel therapeutic strategies that address the multifaceted nature of HS. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), primarily known for managing type 2 diabetes and obesity, possess documented anti-inflammatory and immunomodulatory properties, making them a compelling candidate for HS management.

This systematic review aimed to synthesize existing literature on the efficacy and safety of GLP-1 RAs in treating Hidradenitis Suppurativa. Researchers conducted a comprehensive search to identify relevant studies, applying specific inclusion criteria to ensure data quality and relevance. Ultimately, three publications met these criteria, forming the basis of the review's findings. The primary objective was to evaluate whether GLP-1 RAs could serve as an effective adjunct therapy, particularly in HS patients presenting with obesity and metabolic syndrome. The review assessed both therapeutic outcomes and reported adverse events across the included studies.

The systematic review of three publications revealed preliminary evidence suggesting that GLP-1 RAs may offer beneficial effects in the management of Hidradenitis Suppurativa. The identified studies collectively indicated a potential for GLP-1 RAs to act as an effective adjunct therapy, particularly for patients who also suffer from obesity and metabolic syndrome. The proposed mechanisms for these benefits include the known anti-inflammatory actions of GLP-1 RAs, which could mitigate the immune dysregulation central to HS pathogenesis, alongside their established effects on weight reduction. > The review highlighted that GLP-1 RAs show promise in improving HS outcomes, especially in patients with co-existing metabolic comorbidities, suggesting a synergistic therapeutic effect. However, the abstract did not provide specific quantitative data such as percent reductions in disease activity scores, p-values, or fold-changes from the individual studies. The findings are qualitative, pointing towards a therapeutic direction rather than definitive efficacy metrics.